Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Feb 17, 2017
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its fourth quarter and year end 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 8:00 a.m. ET on Tuesday, February 21, 2017.    To access the ca...
Feb 17, 2017
Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues Warning letter does not restrict the production or shipment of Glatopa 20 mg CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and...
Feb 17, 2017
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with...
Feb 7, 2017
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2016 before the U.S. financial markets open on Tuesday, February 21, 2...
Feb 1, 2017
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, February ...
Jan 31, 2017
CAMBRIDGE, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the United States District Court for the District of Delaware has found each of Teva Pharmaceutical's U.S. Patent Nos. 8,232,250; 8,399,413; 8,969,302; and 9,155,776  invalid as obvious over the prior art. "We are very pleased...
Jan 6, 2017
-- New collaboration and license agreement with CSL to develop Fc multimer programs, including M230, with a $50M upfront license fee -- -- Agreement with Shire to receive full rights to M923 and a $51M one-time return payment -- CAMBRIDGE, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology ...
Jan 5, 2017
--Momenta to receive $50 million upfront license fee and up to $550 million in potential milestone payments from CSL--             --Moment...
Jan 3, 2017
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, President and CEO, will present at the 35th Annual J. P. Morgan Healthcare Conference. The presentation is scheduled for...
Nov 29, 2016
CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with moderate-to-severe chronic plaque psoriasis, met its...
FirstPrevious
2
...
NextLast
= add release to Briefcase